|| List of recent Peptide-related patents
| Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same|
Provided are methods of increasing tolerance of a plant to abiotic stress, and/or increasing biomass, growth rate, vigor and/or yield of a plant. The methods are effected by expressing within the plant an exogenous polynucleotide encoding a polypeptide comprising an amino acid sequence at least 90% homologous to the amino acid sequence selected from the group consisting of seq id nos:201, 207, 212, 202-206, 208-211, 213-391, 1655, 961-1529, and 1660-1663.
| Plants having enhanced yield-related traits and producing methods thereof|
Provided is a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a tlp (tify like protein) polypeptide, a pmp22 polypeptide (22 kda peroxisomal membrane like polypeptide), a rtf (rem-like transcription factor) polypeptide, or a bp1 (bigger plant 1) polypeptide. Also provided are plants having modulated expression of a nucleic acid encoding a tlp, pmp22, rtf or bp1 polypeptide, which plants have enhanced yield-related traits compared to control plants..
| Drought tolerant plants and related constructs and methods involving genes encoding zinc-finger (c3hc4-type ring finger) family polypeptides|
Isolated polynucleotides and polypeptides and recombinant dna constructs useful for conferring drought tolerance, compositions (such as plants or seeds) comprising these recombinant dna constructs, and methods utilizing these recombinant dna constructs. The recombinant dna construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a zinc-finger (c3hc4-type ring finger) family polypeptide..
| Use of aldh7 for improved stress tolerance|
The present invention relates to the field of plant molecular biology, more particularly to the regulation of genes that increase drought tolerance and yield. Provided herein are methods finding use in agriculture for increasing drought tolerance in dicot and monocot plants.
| Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription|
The present disclosure provides a dna-targeting rna that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target dna and/or a polypeptide associated with the target dna. The present disclosure further provides site-specific modifying polypeptides.
| Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency|
The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake.
| Immobilized bioactive hydrogel matrices as surface coatings|
The present invention is directed to a stabilized bioactive hydrogel matrix coating for substrates, such as medical devices. The invention provides a coated substrate comprising a substrate having a surface, and a bioactive hydrogel matrix layer overlying the surface of the medical device, the hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component, the first and second high molecular weight components each being selected from the group consisting of polyglycans and polypeptides, wherein at least one of the first and second high molecular weight components is immobilized (e.g., by covalent cross-linking) to the surface of the substrate..
| Production of high mannose glycosylated proteins stored in the plastid of microalgae|
The present invention concerns a transformed microalga producing a protein harboring a “high mannose” pattern of glycosylation in the plastid of the transformed microalga, wherein 1) the transformed microalga has a chloroplast endoplasmic reticulum (cer); 2) the microalga has been transformed with a nucleic acid sequence operatively linked to a promoter, the nucleic acid sequence encoding an amino acid sequence including (i) an amino-terminal bipartite topogenic signal (bts) sequence composed of at least a signal peptide followed by a transit peptide; and (ii) the sequence of the protein, 3) the xylosyltransferases and fucosyltransferases of the microalga have not been inactivated; 4) the n-acetylglycosyltransferase i of the microalga has not been inactivated, preferably the n-acetylglycosyltranferases ii, iii, iv, v and vi, mannosidase ii and glycosyltransferases of the microalga have not been inactivated.. .
| Peptides for treatment and diagnosis of bone diseases|
The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition.
| Alphabody libraries and methods for producing the same|
The invention provides single-chain alphabody library comprising at least 100 different-sequence single-chain alphabody polypeptides, wherein said alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% but not all of said variegated amino acid residue positions are located either in the loop, helix surface or linker region of the alphabody. The invention further provides methods for use of the alphabody libraries and alphabodies obtainable by the methods of the invention..
| Modified amino acids|
Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis..
| Methods for treating channelopathies|
The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel..
| Transdermal delivery of beneficial substances effected by a hostile biophysical environment|
The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed.
| Functionalized biomaterials for tissue regeneration|
The present invention concerns the field of functionalized self-assembling peptides suitable for obtaining hydrogels for use in a wide range of applications in the biomedical field, such as for the development of biomaterials for regenerative medicine and basic science research.. .
| Novel genes and proteins that home to developing microvessels|
Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to dna that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides.
| Autophagy-inducing peptide|
An autophagy-inducing compound comprises an autophagy-inducing peptide comprising beclin-1 residues 269-283 and a heterologous moiety that promotes therapeutic stability or delivery of the compound. The compound may be used to induce autophagy and in assays with beclin-1 binding partners..
| Novel peptides that are modulators of the protein trf2 and compositions containing same|
Are disclosed herein. The peptide compounds can be used as telomeric repeat-binding factor 2 (trf2) protein-modulating compounds and have a preventive action on deoxyribonucleic acid (dna) double-strand breaks.
| Peptide fragments for inducing synthesis of extracellular matrix proteins|
Short biologically active tetrapeptides are disclosed that are comprised of the sequences gxxg and pxxp where g (glycine) and p (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin.
| Multivalent heteromultimer scaffold design and constructs|
Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof.
| Pharmaceutical composition containing an endocytic motif and protein transduction domains for preventing or treating cancer|
The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of seq id no. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition.
| Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity|
The compositions and methods of the present invention relate to the co-delivery of a molecule and a polypeptide to cells to improve the therapeutic efficacy of the molecules. In one embodiment of the invention, the invention may improve delivery of growth factors by co-delivering these growth factors with their receptors and co-receptors, such as syndecans.
| Polypeptide conjugate|
The disclosure provides polypeptide conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.. .
| Modulators of the gpr119 receptor and the treatment of disorders related thereto|
The present invention relates to compounds of formula i and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a dpp-iv inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an sglt2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a gpr119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.. .
| Subcutaneous delivery of a long-acting natriuretic peptide|
This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided..
| Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide|
A nanoparticle includes a carbohydrate carrier and a bacteriocin. A method for prolonging efficacy of a bacteriocin against a food pathogen includes providing the bacteriocin in a delivery system, and inhibiting the food pathogen by the bacteriocin.
| Peptides and use thereof in the inhibition of angiotensin converting enzyme|
Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides..
| Methods for using semaphorin polypeptides|
The present invention provides uses and methods of using a sema3e polypeptide and a sema3e polynucleotide encoding a sema3e polypeptide. The methods include decreasing airway remodeling in a subject, treating asthma in a subject, treating a subject having, or at risk of having, acute asthma, and reducing inflammation of a subject's airway.
| Methods for recovering peptides/amino acids and oil/fat from one or more ...|
According to a first aspect, hydrolysis of a protein-containing raw material and separation of amino acids/peptides is carried out, wherein the hydrolysis is effected by using the endogenous enzymes of the protein-containing raw material. The hydrolysate is passed through a membrane filter, wherein peptide/amino acids follow a permeate stream, whilst the active enzymes continuously break down any protein residues that are deposited on the membrane surface.
| Method for the production of reading-frame-correct fragment libraries|
The present invention relates to reading-frame-correct fragment libraries, methods for their production, and the use of the fragment libraries for selection of functional polypeptide variants with improved properties.. .
| Ps-spcl searching apparatus and method using surface plasmon resonance|
A positional scanning-synthetic peptide combinatorial library (ps-spc) searching apparatus and method using surface plasmon resonance (spr) are provided. The method includes spotting and fixing each of a plurality of peptide pools to a top of one thin metal film, inputting specific materials to the top of the thin metal film, applying a tm-mode light to a bottom of the thin metal film and exciting spr for the thin metal film, and detecting a tm mode reflected light reflected from the thin metal film and displaying the detected light as a two-dimensional image..
| Structures of human histidyl-trna synthetase and methods of use|
Provided are histidyl-trna synthetase variant polypeptides, x-ray crystallographic and nmr spectroscopy structures of hrs polypeptides, and related compositions and methods for therapy and drug discovery.. .
| Method for stabilizing protein|
An excellent protein stabilizer is provided, which has the following effects: (1) low probability with contamination of pathogens, (2) the effect of stabilization on photoproteins, and (3) minimization of loss of activity under lyophilizing conditions. A peptide from fish is used as the active ingredient for the protein stabilizer..
| Method of prognosing and diagnosing hereditary spastic paraplegia, mutant nucleic acid molecules and polypeptides|
A method for diagnosing the presence of hereditary spastic paraplegia (hsp) or predicting the risk of developing hsp in a human subject, comprising detecting the presence or absence of a defect in a gene encoding a polypeptide comprising the sequence of fig. 9 (seq id no: 19), in a nucleic acid sample of the subject, whereby the detection of the defect is indicative that the subject has or is at risk of developing hsp..
| Enrichment and purification of infectious prion protein|
Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein.. .
| Antibodies as t cell receptor mimics, methods of production and uses thereof|
A methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of hla molecules, is disclosed. These antibodies may be utilized in therapeutic methods of mediating cell lysis..
| Peptides and methods for inducing cell death|
The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein.
| Novel glycoside hydrolases from thermophlic fungi|
The present invention relates to isolated polypeptides having cellulolytic activity or hemicellulolytic activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
| Separatome-based protein expression and purification platform|
Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of e. Coli, yeast, bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc.
| Polypeptides having cellobiohydrolase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having cellobiohydrolase activity, catalytic domains, and cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains, and cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, or cellulose binding domains..
| Cldn5 mini-promoters|
Isolated polynucleotides comprising a cldn5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
| Method for the regulation of protein kinase activity in vivo and in vitro|
Disclosed herein is a substantially pure nucleic acid encoding a eukaryotic protein kinase having at least one mutated amino-acid residue located in its subdomain ix. Also disclosed is a substantially pure eukaryotic protein kinase polypeptide having at least one mutation in its subdomain ix, the kinase being encoded by the nucleic acid..
| Polypeptide linker and method of analyzing target material using the same|
A polypeptide linker comprising an antibody-binding region and an enzyme cleavage region, and related compositions, kits, and methods of using same.. .
| Isotopically-labeled proteome standards|
The invention provides methods for quantifying biomolecules, such as polypeptides in mass spectrometric analysis. The methods include use of a biomolecule standard having at least one atomic isotope different than that of the naturally occurring isotopes in the biomolecule of interest.
| Isoltation of factors associated with nucleic acid|
Methods for screening and isolating peptide, polypeptide, protein complexes and non-coding nucleic acids that are associated with selected target genomic locus are provided. The methods comprise the steps of obtaining a sample that comprises a modified target genomic dna sequence and one or more peptide, polypeptide, protein complexes and non-coding nucleic acids as with that dna sequence.
| Perfluorinated compounds for the non-viral transfer of nucleic acids|
The invention relates to a compound of general formula (i): a-b-c(f, g′)-d-e-f-g-a′ or a structure of general formula (ii): a-b-c-(f′, g′)-d-b-e-f-g-a′ (ii), wherein -a is at least one molecule selected from the group of the perfluorocarbons (pfcs), perfluorinated silicon compounds, and/or further perfluorinated compounds, -b is at least one predetermined breaking point in the form of a physically, chemically, or enzymatically severable bond, -c is absent or at least one linker molecule, -d is absent or at least one spacer molecule, -e is at least one molecule selected from the group containing nucleobases, nucleosides, nucleotides, oligonucleotides, nucleic, acids, modified nucleobases, modified nucleosides, modified nucleotides, modified oligonucleotides, modified nucleic acids, monomers of peptide nucleic acids, oligomers or peptide nucleic acids and peptide nucleic acids or other nucleic acid analogs, -f, f′ is absent or at least one ligand, -g, g′ is absent or at least one marker molecule, -a′ is absent or has the meaning of a, and wherein the compounds i), ii), iii), iv), v), vi) are excluded. The invention farther relates to the use of said compound for the non-viral transfer of molecule e into a cell, to a pharmaceutical composition containing said compound, and to the use of said pharmaceutical composition..
| West nile virus vaccine, and method for production thereof|
The invention provides virus-like particles (vlp) highly secreting or producing signal peptide obtained by altering a signal sequence derived from west nile virus (wnv), the signal peptide, a wnv vlp secretion expression vector containing a nucleic acid encoding prm protein and e protein, a wnp vlp highly secreting or producing animal cell line harboring the vector, a wnv vaccine containing wnv vlp obtained by the cell line as an active ingredient, and a wnv dna vaccine containing the vlp secretion expression vector as an active ingredient.. .
| T-cell death-inducing epitopes|
Cell death-inducing epitopes and polypeptides containing same. Also disclosed are compounds for inducing death of activated t-cells, a method of producing antibodies to the epitopes, a method of identifying compounds that bind to the epitopes, a method of inducing death of activated t-cells, and pharmaceutical compositions containing the compounds..
| Carrier peptides for cell delivery|
The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology..
| Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes|
The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell.
| Site-specific labeling methods and molecules produced thereby|
The present invention provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates..
| Human igm antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system|
Antibodies, particularly human antibodies, are disclosed having activity in treatment of demyelinating diseases and diseases of the central nervous system. Neuromodulatory agents are provided comprising a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, and active fragments, monomers and combinations thereof having one or more of the following characteristics: capable of inducing remyelination; binding to neural tissue; promoting ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells.
| Neutralizing antiboides to nipah and hendra virus|
The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of nipah virus and/or hendra virus..
| Methods for treating melanoma|
Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a dll4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human dll4) to a subject.
| Anti-n3pglu amyloid beta peptide antibodies and uses thereof|
The present invention provides anti-n3pglu aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-n3pglu aβ antibodies or antigen-binding fragment thereof for the treatment of alzheimer's disease..
| Treatment for ige-mediated disease|
The invention provides an endos polypeptide, or a polynucleotide encoding an endos polypeptide, for use in a method for treating or preventing a disease or condition mediated by ige antibodies.. .
| Proteins for use in human and animal staphylococcus infections|
The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in seq id no:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors.
| Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1|
The present invention relates to novel polymer conjugates of polypeptide variants of the hmgb1 high affinity binding domain box-a (hmgb1 box-a) or of a biologically active fragment of hmgb1 box-a. Further, the invention relates to novel polymer conjugates of polypeptide variants of the hmgb1 high affinity binding domain box-a (hmgb1 box-a).